Podcasts about Atopic dermatitis

Send us Fan MailHe spent decades interviewing some of the toughest athletes on the planet. Meanwhile, he was quietly battling a condition that at times covered nearly his entire body. Today, for the first time, Paul shares the story behind the story.Paul is an 11-time Emmy Award-winning sports television producer whose career has taken him behind the scenes of some of the biggest moments in sports and entertainment.For more than sixteen years, Paul served as a senior producer, helping create acclaimed documentaries, television series, and feature programming seen by millions. Along the way he has interviewed and produced stories featuring some of the most recognizable names in sports and popular culture, including Tom Brady, Peyton Manning, Michael Jordan, Steph Curry, Charles Barkley, Deion Sanders, Eminem, and many others.Paul has led large-scale productions, won multiple national Emmy Awards, and directed feature-length documentaries, including projects that reached the top of the streaming charts.But behind that successful career was a challenge most viewers never knew about.Since childhood, Paul has lived with severe eczema, a chronic inflammatory skin condition that at times affected nearly his entire body. The condition impacted everything from sleep and travel to confidence, comfort, and everyday interactions. For years he largely kept those struggles private while continuing to work in some of the most visible and demanding environments in professional sports media.Today we'll talk about Paul's remarkable career in sports storytelling, what it was like navigating a visible chronic condition in a culture that often celebrates toughness and silence, and why broader conversations around men's health need to include conditions that affect quality of life, mental well-being, and self-confidence.Important Episode Links - Nemluvio Web Page - https://www.nemluvio.com/Nemluvio Safety Information - https://www.galderma.com/sites/default/files/2024-12/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdfNemluvio FDA Approval Press - https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients-moderate-severe-atopic#MensHealth #EczemaAwareness #ChronicIllness #InvisibleIllness #AtopicDermatitis #MentalHealth #HealthAndWellness #SportsMedia #NFLFilms #Resilience #QualityOfLife #HiddenStruggles #Nemluvio #MensHealthMonth #HealthAwareness #PersonalStory #PodcastInterview #ProgressPotentialPossibilities #PPPShow #ChronicDisease #InspirationSupport the show

Are you confident diagnosing and managing eczema in patients with skin of colour (SOC)? Atopic dermatitis is one of the most common skin conditions in Australia, yet it often goes unrecognised or is underestimated in patients with SOC. The classic signs we rely on (bright erythema, flexural distribution) may look very different in patients with SOC. The result of this is missed diagnoses, delayed treatment, and real quality-of-life consequences for your patients. This webinar and Q&A with Brisbane-based specialist dermatologist Dr Stephanie Rea takes GPs beyond the textbook to explore how atopic dermatitis truly presents across all skin types. Drawing on relevant clinical cases, Dr Rea shares practical tools to sharpen your diagnostic confidence, navigate the pitfalls, and implement culturally informed management strategies you can put into practice from the very next consultation. Delivered in collaboration with CeraVe, the session teaches you how to: Spot the clinical clues of atopic dermatitis across various skin phototypes Recognise follicular accentuation, papular and discoid variants, and post-inflammatory pigment changes Avoid common diagnostic pitfalls and not-to-miss differentials Understand the role of ceramides and skin barrier repair in this patient population Choose appropriate skin care and prescribe topical and systemic therapies for treating atopic dermatitis in SOC The webinar includes Q&A and case discussions. Prefer a visual format? Watch this podcast here.   About Dr Stephanie Rea MBBS (Hons), MPH, MMed, FACD Dr Stephanie Rea is a specialist Dermatologist and a Fellow of the Australasian College of Dermatologists. She holds dual Masters in Public Health and Sexual and Reproductive Health. Dr Rea runs a complex medical Dermatology clinic at the Princess Alexandra Hospital and is the clinical lead of the Combined Dermatology and Sexual Health Multidisciplinary Clinic at the Royal Brisbane and Women's Hospital. She maintains an academic appointment as a Senior Lecturer at the University of Queensland and is involved in rural outreach clinics in Far North Queensland. Dr Rea has a private practice at South East Dermatology in Annerley. Dr Rea has a strong interest in medical dermatology including eczema, psoriasis, acne, genital dermatology, autoimmune related skin disorders and skin cancer.    Next steps in your learning journey

Send me a derm question or story through text or voicemail!Skin barrier is having a moment... and for good reason. In this episode, I break down why restoring the skin barrier is a non-negotiable piece of the multimodal approach to managing atopic dermatitis in dogs and cats, and more importantly, how to actually do it when your clients can't keep up with a bathing schedule.Watch The Episode: https://www.youtube.com/@thedermvet3932Follow The Derm Vet Podcast: https://www.instagram.com/thedermvetpod/Follow Me: https://www.instagram.com/thedermvet/Timestamps00:00 Intro00:45 Itch Inquiry: Recurrent Yeast Otitis01:37 Antifungal Resistance in Malassezia03:54 Underlying Allergies and Immunotherapy06:29 Paronychia07:19 Toothpick vs. Tape Methods09:30 Treatment for Yeast15:35 Summary/Outro 

In this episode, host Jenn Dawson talks with Dr. Dawn Davis, Dr. Amy Paller, and Dr. Larry Eichenfield about the newly published pediatric atopic dermatitis guidelines and what they mean for clinicians, patients, and families. Together, they unpack the evidence behind prevention, comorbidities, and treatment recommendations, discuss how rapidly the therapeutic landscape is evolving, and highlight the biggest unanswered questions that remain in research. The conversation also explores the importance of patient advocacy, shared decision-making, and improving access to care as the field moves toward more personalized treatment.Guidelines of care for primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.Guidelines of care for the management of atopic dermatitis in pediatric patients.Please click here for a list of speakers' conflicts of interest.

Dr. Marty Makary out as FDA Commissioner—was he the victim of a BigPharma purge? Are “liquid biopsies” useful for predicting recurrences, as well as guiding therapy, for cancer? Nighttime smartphone by adolescents surges, eroding kids' sleep needs; Persistent itch may require an “all of the above” approach to break its vicious cycle—could topical vitamin B12 provide an answer? Study critiques research methods that fast-tracked new Alzheimer's drugs.

What comes first: the obesity or the skin inflammation?  We've got just the expert to help us find out. This week, we're joined by Dr. Ganary Dabiri as she walks us through the relationship of obesity and the skin. Listen in as she discusses skin diseases, how to use "people first" language, and the clinical possibilities of GLP-1 medications. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Dr. Ganary Dabiri is double board-certified in Dermatology and in Obesity Medicine. She earned her graduate and medical degree from Albany Medical College. She completed her Dermatology Residency at Roger Williams Medical Center. In 2024 she completed her requirements and obtained board certification in Obesity Medicine. Dr. Dabiri is an adjunct assistant professor at Albany Medical College. She works in private practice in Milford, Massachusetts. In 2024, Dr. Dabiri started the first Skin Inflammation and Obesity Medicine Specialty Clinic in Massachusetts. This comprehensive clinic focuses on and treats patients not only for their chronic inflammatory dermatologic condition such as Psoriasis, Hidradenitis Suppurativa, PCOS, and Atopic Dermatitis but treats their concurrent obesity. Since the inception of this clinic, she has helped numerous patients achieve clearer skin, improve their joint health, but equally if not more importantly - improve their overall health.

Broadcast from KSQD, Santa Cruz on 5-07-2026: Dr. Dawn debunks the 1971 "220 minus age" maximum heart rate formula, noting a 2025 study found individual predictions were off by up to 20 beats per minute. She recommends the Tanaka equation (208 minus age) times 0.7, but emphasizes tracking improvement trends rather than absolute numbers. ConsumerLab testing found Safe Catch Wild Elite Pure Tuna and Wild Ahi Yellowfin Tuna had no detectable mercury, prompting Dr. Dawn to reconsider eating tuna after years of avoidance due to concerns about mercury bioaccumulation and its effects on nerve microtubules. A meta-analysis of 115 studies involving 55,000 men found limiting ejaculation before IVF leads to increased sperm DNA damage and poorer motility. Clinical trials showed 46% IVF pregnancy rates with less than 48 hours abstinence versus 36% with longer periods. A personalized mRNA vaccine for pancreatic cancer showed striking results: of 16 patients whose tumors were surgically removed, half produced killer T-cells targeting cancer, and seven of those eight remain alive six years later. Pfizer and Valneva's Lyme disease vaccine reduced infection by over 70% in a trial of 9,400 people ages five and up. Nearly half a million Americans contract Lyme annually, and chronic infection can cause nervous system damage and chronic fatigue. Dr. Dawn explores the gray-market peptide ecosystem, where compounds are sold as "research chemicals" with wink-and-nod marketing. A 2018 Belgian study found purity levels ranging from 5% to 99.9%, with some samples containing arsenic, lead, or industrial contaminants. A study of 450 people found that blocking smartphone internet access for two weeks improved sustained attention equivalent to reversing 10 years of age-related cognitive decline, with depression symptom improvements comparable to cognitive behavioral therapy. A multi-country study of 241 unresponsive patients found that 25% showed brain activity indicating consciousness when asked to imagine playing tennis during advanced brain scans. Scientists call this cognitive motor dissociation, and by some estimates tens of thousands of Americans may be misdiagnosed. Chinese researchers grew functional adrenal cortex organoids that responded to pituitary hormones and produced cortisol when transplanted into mice. They also introduced genetic mutations to create organoid models of Cushing's syndrome for drug testing. A Science paper identified the neural pathway connecting psychological stress to eczema flare-ups: sympathetic neurons from the stellate ganglion recruit eosinophils to the skin. Researchers traced the pathway using pseudo-rabies virus injected into skin. Mouse studies showed prenatal stress causes elevated corticosterone in amniotic fluid, which activates fetal mast cells derived from the yolk sac. Offspring develop eczema-like lesions in areas receiving mechanical stimulation, but symptoms resolve around 24 weeks when bone marrow-derived mast cells replace the activated ones. Callers ask about CBN side effects. Dr. Dawn explains cannabinoids prolong anandamide's calming effects by slowing its breakdown, and considers 30-45mg over a night reasonable, but cautions against escalating doses given limited research.

In this episode of The Cutaneous Connection, Dermatology Times revisits a recent video episode of the Derm Dispatch show where host Renata Block, DMSc, MMS, PA-C, sits down with Zachary Rubin, MD — allergist, pediatrician, and New York Times bestselling author of All About Allergies — to explore the intersection of dermatology and allergy. Together, they tackle one of the most persistent myths in practice: that food elimination can treat atopic dermatitis. Dr. Rubin breaks down the difference between IgE-mediated allergic reactions and the complex inflammatory nature of eczema, explains the atopic march, and discusses how understanding the gut-lung-skin axis can empower patients to take charge of their care. The conversation also covers the latest treatment advances — from JAK inhibitors to novel biologics — and touches on indolent systemic mastocytosis and the truth about so-called hypoallergenic dogs. A must-listen for any clinician treating allergic and inflammatory skin disease.For more content, visit https://www.dermatologytimes.com/

Send me a derm question or story through text or voicemail!In this episode, we take a closer look at the often-overlooked areas of the dermatologic exam in allergic dogs—because the clues you're missing may be the ones that matter most. From the ventral neck and axilla to claw folds, lip margins, and perianal regions, these hidden sites frequently harbor early or persistent lesions that can shape your diagnosis and treatment plan. We'll discuss why these areas are commonly skipped, what subtle findings to look for, and how a more thorough dermatology exam can improve case outcomes.Tune in for practical tips to elevate your dermatology exams, catch lesions earlier, and avoid missing key pieces of the allergy puzzle.Want to ask a question or share a story to be featured on the podcast? Tap the link at the top of the show notes to text an inquiry or leave a voicemail!Timestamps00:00 Intro01:57 Ventral Neck03:14 Axilla04:21 Claw Folds06:05 Lip Margins07:28 Perianal Region08:51 Pinna10:23 Other Folds 13:14 Review/Summary15:55 Outro

Join us for an enlightening conversation about existing, newly approved, and "coming soon" treatments for kids suffering from eczema -- from pills, to injections, to creams. In this two-part series, GPER's Executive Director interviews expert Dr. Peter Lio of the Chicago Integrative Eczema Center about the latest therapies for kids and explores how to choose between them ... and what's on the horizon based on news from the American Academy of Dermatology Annual Meeting. Learn more about how these treatments work and who they are best suited for in this 30-minute episode that is sure to offer insights -- and hope.Further reading:Atopic Dermatitis at AAD: Longer Dosing, Faster Itch Relief, and New MechanismsThe GPER Treatment Navigator for ParentsConflict of Interest Statements:GPER has received sponsorships and grants from companies who develop treatments for eczema. These can be viewed at: www.gper.org/corporatecouncil

Treatment for atopic dermatitis has changed dramatically, with new therapies offering more targeted relief across the severity spectrum. This course highlights recent drug approvals, updated guideline recommendations, and the clinical implications of managing atopic dermatitis as a chronic inflammatory condition. You will learn how pharmacists can guide therapy decisions, enhance adherence, and improve patient outcomes in personalized atopic dermatitis care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTMelanie Plotke, PharmDManager, Clinical ResearchAmerican Academy of Dermatology Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the updated treatment landscape for atopic dermatitis, including new topical and systemic options.2. Identify opportunities for pharmacists to collaborate and support atopic dermatitis management through therapy recommendations, patient education, and adherence strategies.Rachel Maynard and Melanie Plotke have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-074-H01-PInitial release date: 4/13/2026Expiration date: 4/13/2027Additional CPE details can be found here.

Treatment for atopic dermatitis has changed dramatically, with new therapies offering more targeted relief across the severity spectrum. This course highlights recent drug approvals, updated guideline recommendations, and the clinical implications of managing atopic dermatitis as a chronic inflammatory condition. You will learn how pharmacists can guide therapy decisions, enhance adherence, and improve patient outcomes in personalized atopic dermatitis care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsMelanie Plotke, PharmDManager, Clinical ResearchAmerican Academy of DermatologyGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the updated treatment landscape for atopic dermatitis, including new topical and systemic options.2. Identify opportunities for pharmacists to collaborate and support atopic dermatitis management through therapy recommendations, patient education, and adherence strategies.Rachel Maynard and Melanie Plotke have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-074-H01-PInitial release date: 4/16/2026Expiration date: 4/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Send me a derm question or story!Allergy cases can be REALLY tough!In this week's podcast episode, we explore how veterinarians and staff can build confidence using the full range of allergy medications available. From JAK inhibitors to monoclonal antibodies to cyclosporine, I discuss the importance of knowing the mechanisms and clinical applications of these medications. Atopic dermatitis is a syndrome with many layers. You can have your favorite allergy drugs, but there will always be difficult cases that don't respond and we need to try something different.Tune in for practical insights, real-world case strategies, and tips to help you feel more comfortable navigating complex allergic conditions. Studies:https://pubmed.ncbi.nlm.nih.gov/34344611/https://pubmed.ncbi.nlm.nih.gov/20887404/Timestamps00:00 Intro00:44 New Segments Starting Soon02:07 Being Comfortable w/ Allergy Medications03:25 Breed-Specific Allergy Phenotypes05:07 JAK Inhibitors06:45 Monoclonal Antibodies08:36 Cyclosporine09:58 Summary12:41 Outro

In this episode of the Science of Skin Podcast, board-certified dermatologist Dr. Ted Lain sits down with world-renowned eczema and atopic dermatitis expert Dr. Peter Lio, founder of the Chicago Integrative Eczema Center, to unpack a game-changing shift in how dermatologists think about chronic inflammatory skin conditions. If you're a dermatologist, skincare professional, or someone managing eczema, psoriasis, seborrheic dermatitis, or other steroid-responsive skin conditions — this episode is essential listening. What you'll learn: Why topical corticosteroids, despite being effective, carry real risks with long-term use — including skin atrophy, growth suppression in children, HPA axis suppression, and the increasingly recognized phenomenon of topical steroid withdrawal (TSW) What PDE4 (phosphodiesterase 4) is, how it drives the inflammatory cascade in atopic dermatitis, and why targeting it is a "Goldilocks" approach to treatment The evolution of PDE4 inhibitor topical therapies, including roflumilast (Zoryve) — its origins as an oral COPD drug and its transformation into a highly effective topical for eczema, psoriasis, and seborrheic dermatitis The concept of "PDE4 inhibitor-responsive dermatoses" — a new framework introduced in Dr. Lio's JAAD publication that expands the clinical use of this drug class across a wide range of skin conditions, including rare and pediatric diseases with zero FDA-approved treatments The excellent safety profile of topical roflumilast, including what side effects to watch for and how to counsel patients Why dermatologists must continue championing innovation in topical therapies — not just biologics — to serve patients with mild-to-moderate disease Featured guest: Dr. Peter Lio, MD — Clinical Assistant Professor of Dermatology and Pediatrics, Northwestern University; Founder, Chicago Integrative Eczema Center; Global speaker, researcher, and consultant in atopic dermatitis and inflammatory skin disease. Sponsored by Arcutis Biotherapeutics, makers of roflumilast (Zoryve) topical foam and cream. This episode was recorded ahead of the 2026 AAD Annual Meeting. Link to Dr. Lio's JAAD publication on PDE4 inhibitor-responsive dermatoses. DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment See omnystudio.com/listener for privacy information.

This episode features Dr. Maria Teresa García-Romero, MD MPH from the National Institute of Pediatrics in Mexico City, talking about the skin microbiome and how it relates to atopic dermatitis. The skin microbiome varies widely at different sites on the body, but in general, increased diversity is associated with healthy skin. In atopic dermatitis, Staphylococcus aureus becomes abundant and skin microbiome diversity decreases, correlating with inflammatory responses. Treatments have the effect of reducing Staphylococcus aureus. These bacteria are now established to have a role in the pathophysiology of the disease. The caution with antibiotic treatment is that a systematic review and meta-analysis from Dr. García-Romero's group found Staphylococcus aureus isolates from people with atopic dermatitis had suboptimal susceptibility to commonly used antimicrobials, especially in lower middle-income and upper middle-income countries. Mechanistically, Staphylococcus aureus decrease natural antimicrobial molecules in the skin, stimulate the innate immune response, and likely reduce beneficial bacteria. New treatments are urgently needed because atopic dermatitis is very prevalent (affecting 20-30% of the population), with far-reaching effects in children's and families' lives. Two ingested probiotics are commercially available for atopic dermatitis, backed by clinical data, whereas topical probiotic treatments require further research. Episode abbreviations and links: Paper showing how treatments for atopic dermatitis help the skin microbiome more closely resemble healthy controls: The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment Systematic Review and Meta-Analysis looking at susceptibility of atopic-dermatis associated Staphylococcus aureus to antibiotics in different regions of the world: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis About Dr. Maria Teresa García-Romero: Dr. Maria Teresa García-Romero is a medical doctor graduated from Tec de Monterrey School of Medicine, magna cum laude. She has a Specialty in Dermatology and Diploma in Medical Mycology from UNAM, Mexico City. Dr. García-Romero completed a Fellowship in Pediatric Dermatology at the University of Toronto, and a Master's degree in Public Health and Quantitative methods of research at Harvard University Chan School of Public Health. She has received meritorious awards including the Mexican Foundation for Health (FUNSALUD), Harvard University Presidential Award, Society for Pediatric Dermatology Fellow Award, among others; and funding for research projects by prestigious international organizations such as MIT (Massachusetts Institute for Technology) seed funds and EB Research Partnership. She is currently an attending physician in the Dermatology Department of the National Institute of Pediatrics in Mexico City and a member of the National System of Researchers level II. She has more than 150 articles published in national and international magazines, supervised multiple postgraduate theses and has presented in multiple forums worldwide. Dr. García-Romero is a member of the Editorial Committee of JAMA Dermatology, Pediatric Dermatology and other high impact journals. Her research interests include the skin microbiome, atopic dermatitis, vascular anomalies and autoimmune disease.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative landscape of the pharmaceutical and biotechnology sectors, where scientific innovation, regulatory progression, and strategic adjustments define the industry's current trajectory.A significant spotlight is on Bayer's recent clinical success with Kerendia (finerenone) in treating non-diabetic chronic kidney disease (CKD). Previously approved for CKD linked with type 2 diabetes, the positive outcomes from the FIND-CKD study suggest an expanded therapeutic scope for Kerendia. This advancement not only enhances Bayer's foothold in nephrology but provides a potential new treatment avenue for millions suffering from CKD without diabetes, underscoring the urgent global need to address this chronic condition effectively.In parallel, Eli Lilly's promising Phase 3 trial results for Ebglyss, an IL-13 inhibitor intended for atopic dermatitis in children, signal a potential expansion of treatment options for younger patients. Atopic dermatitis can severely impact quality of life, and Lilly's progress illustrates a broader industry commitment to fulfilling unmet medical needs across various patient groups.Turning to regulatory achievements, AstraZeneca's Imfinzi has secured European Union approval for perioperative use in gastric cancer treatment. This development underscores a growing regulatory momentum favoring oncology therapies and highlights an increasing emphasis on perioperative cancer care. Such advancements are crucial as they aim to improve surgical outcomes and enhance long-term survival rates for cancer patients.The industry is also navigating significant challenges as major drug patents approach expiration in 2026. The looming end of exclusivity spells increased competition from generics and presses companies to innovate or optimize mature product portfolios. This situation necessitates strategic agility as firms endeavor to sustain revenue streams amid pricing pressures.In a legal context, Johnson & Johnson has filed a lawsuit against a former oncology employee now associated with Summit Therapeutics, alleging theft of trade secrets. This case highlights the intense competitive nature within biopharma and the critical importance of protecting intellectual property in a fiercely contested market.Meanwhile, Structure Therapeutics has reported compelling phase results for aleniglipron, an oral GLP-1 drug candidate achieving a 16% weight loss efficacy. This positions aleniglipron as a strong player in obesity management innovations, showcasing ongoing advancements in metabolic disease treatment strategies. The drug demonstrated significant weight loss results over 44 weeks in Phase 2 trials, setting the stage for further program launches this year and suggesting potential competition with industry leaders like Novo Nordisk and Eli Lilly by offering less invasive therapy alternatives.BioMarin's reassessment of its clinical strategies for Voxzogo studies reflects mounting competition in treating achondroplasia. This move illustrates broader industry challenges where companies must balance development priorities against competitive pressures effectively. However, BioMarin has faced setbacks after temporarily halting dosing and enrollment in two studies of its growth-related drug Voxzogo due to safety concerns following hip injury reports. This development emphasizes vigilance in monitoring drug safety profiles during trials within competitive therapeutic areas.Amazon's intriguing entry into healthcare with its AI health agent marks a potential revolution in patient engagement by delivering personalized health insights and enhancing access to healthcare professionals. This convergence of technology and healthcare bears significant implications for future patient care delivery models.RegulatSupport the show

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!RAINIER: Povetacicept Reduces Proteinuria By 52.0%A pre-specified week 36 interim analysis of the phase 3 RAINIER trial found that povetacicept, a dual BAFF/APRIL inhibitor, reduced proteinuria by 52% from baseline and achieved a statistically significant 49.8% reduction in UPCR versus placebo in patients with IgA nephropathy.Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA TrialThe FDA accepted Mineralys Therapeutics' NDA for lorundrostat as an add-on treatment for hypertension, supported by phase 3 and phase 2 trial data, with a PDUFA action date set for December 22, 2026.Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan BudiniNew findings indicate that stopping GLP-1 receptor agonist therapy leads to a predictable pattern of weight regain—reaching approximately 60% at one year before plateauing—suggesting meaningful but substantially diminished long-term benefit after cessation.FDA Approves Leucovorin Calcium (Wellcovorin) Tablets as First Cerebral Folate Deficiency TreatmentThe FDA approved GSK's leucovorin calcium tablets as the first treatment for cerebral folate deficiency in patients with a confirmed FOLR1 gene variant, based on a systematic review of published literature and mechanistic data.New Long-Term Data Announced on Roflumilast Cream for Atopic Dermatitis in ChildrenLong-term data from the INTEGUMENT-OLE extension study show that once-daily roflumilast cream 0.05% is safe and well-tolerated in children aged 2 to 5 with mild-to-moderate atopic dermatitis, with efficacy not only sustained but continuing to improve through 56 weeks of treatment.

In this episode of the DIGA Podcast, we continue our Dermatology Crash Course mini-series with a high-yield discussion on atopic dermatitis led by Dr. Peter Lio. We hope you enjoy!About the Dermatology Crash Course Series The Dermatology Crash Course is a DIGA Podcast mini-series focused on delivering short, high-yield episodes that cover foundational dermatology topics. Each episode features a dermatologist sharing practical insights to help learners develop confidence in recognizing and managing common skin conditions.Learn More:Educational links: - Dr. Lio's Pediatric Atopic Dermatitis Presentation- National Eczema Association- Chicago Integrative Eczema Center- peterlio@gmail.com ---DIGA Instagram: @derminterestToday's Host, George: @georgepapadeas--- For questions, comments, or future episode suggestions, please reach out to us via email at derminterestpod@gmail.com ---District Four by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3662-district-fourLicense: https://filmmusic.io/standard-license---

Send me a question or story!This is the last installment in our series of DERM DRUGS. Monoclonal antibodies are becoming an important tool in veterinary dermatology — but what are they, and how do they actually work?In this episode, we break down monoclonal antibody therapy in practical terms. We explain how these targeted treatments are designed to recognize and block specific molecules in the immune system, helping reduce itch in allergic dogs without broadly suppressing immunity.We discuss commonly used products like Cytopoint which targets IL-31, a key cytokine involved in pruritus. We also introduce the announcement of an upcoming (not yet released) product called Befrena, another monoclonal antibody therapy, and what we know about this therapy today.00:00 – Intro02:07 – What is a Monoclonal Antibody03:18 – Cytopoint Basics05:35 – Potential Side-Effects06:33 – Befrena Basics08:44 – Overview09:22 – Outro

Send me a question or story!Janus kinase (JAK) inhibitors have become a cornerstone in managing pruritic and allergic skin disease in dogs by targeting the JAK-STAT signaling pathway, which transmits itch and inflammatory cytokine signals. With so many medications hitting the market, it is important to understand the differences between all of the different JAK inhibitors in veterinary medicine.Apoquel (oclacitinib) has been in the veterinary field the longest with over a decade of use. However, Zenrelia (ilunocitinib) has been available in many countries for over a year. Additionally, Numelvi (atinvicitinib) has recently become available in Europe and will hit the market in the United States very soon (with others to follow). Learn about the differences in these medications and why it is important to become comfortable with all of them on this week's episode of The Derm Vet podcast.Timestamps00:00 Intro01:35 JAK Inhibitor Basics02:35 What are JAK Receptors03:31 Apoquel and Zenrelia 05:20 Numelvi 07:57 How To Tell If a Pet Is Atopic 09:12 Are JAK Inhibitors Safe with Neoplasia11:32 What Does JAK Selectivity Mean 13:47 Common Side-Effects of JAK Inhibitors 17:01 Using JAK Inhibitors Off-Label18:51 Outro

Unlike a simple infection with a clear-cut cure, canine atopic dermatitis (CAD) is an inflammatory, chronic condition with complex causes. Treating it with a one-size-fits-all approach is like trying to put a Yorkshire terrier's sweater on a Great Dane—it will not work. In this episode of the VetFolio Voice podcast, discover the nuances in treating atopic dermatitis and finding the best fit for the individual patient. We explore how to alleviate pruritus while ruling out pruritic diseases that mimic atopy. Join us as we go from syndrome to solution in providing relief for your patients with CAD.

Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar and Dr. Peter Lio discuss significant advancements in dermatology, including the recent approval of an ICD 10 code for topical steroid withdrawal, the exploration of botanicals in skin treatment, and the emerging understanding of the gut-skin connection. They also delve into the role of GLP medications in managing skin conditions and the exciting future developments in dermatology, particularly in the treatment of atopic dermatitis. Read the referenced documents at the following sites: - Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy: https://doi.org/10.1016/j.jdrv.2025.12.008 - The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis: https://jintegrativederm.org/article/view/109 - Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+: https://www.medrxiv.org/content/10.1101/2024.04.17.24305846v1.full-text - Jennifer Fugo information: https://www.skinterrupt.com/book-a-session/ Takeaways - The CDC has approved an ICD 10 code for topical steroid withdrawal. - This approval allows for better study and understanding of TSW. - Diagnostic criteria for TSW are still being developed. - Topical steroid withdrawal may overlap with severe atopic dermatitis. - Non-steroidal treatments are becoming more prominent in dermatology. - Botanicals have been used across cultures for skin treatment. - The gut-skin connection is gaining attention in dermatology. - GLP medications may play a significant role in dermatological treatments. - The future of dermatology is promising with new treatments on the horizon. - A holistic approach to skin health is essential for effective treatment. Chapters 00:00 - Introduction to Dermatology Innovations 01:43 - Topical Steroid Withdrawal Breakthroughs 06:53 - Exploring Botanicals in Dermatology 09:15 - Gut-Skin Connection and Metabolic Health 13:42 - The Role of GLPs in Dermatology 19:42 - Future of Dermatology: Exciting Developments

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for January 18-24, 2025:1. Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPenInterim phase 2 data suggest NS002 intranasal epinephrine may provide more rapid systemic exposure than intramuscular autoinjectors, supporting its potential as a needle-free option for anaphylaxis management.2. AHA 2026 Heart Disease and Stroke Statistics: Progress and Pitfalls, With Latha Palaniappan, MD, MSThe AHA's 2026 Heart Disease and Stroke Statistics highlight persistent gaps in cardiovascular prevention and outcomes despite advances in treatment, with continued emphasis on heart disease and stroke as leading causes of mortality in the US.3. New CHEST Recommendations Guide Biologic Use for Severe AsthmaCHEST released updated guidance to help clinicians individualize biologic selection for severe asthma based on patient characteristics, disease phenotype, and available evidence.4. Topical Steroid Concerns in Dermatology Highlighted in Nationwide SurveyA nationwide survey underscores widespread patient and caregiver concerns about long-term topical steroid use in chronic inflammatory skin diseases and a perception that current management strategies are largely reactive rather than preventive.5. Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and OlderPhase 3 data show amlitelimab was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis, supporting its role as a targeted, non–T-cell-depleting biologic option.

For primary care providers, seeing a patient presenting with atopic dermatitis (eczema) is common, yet misconceptions persist regarding its underlying cause and optimal management. This episode tackles the critical clinical dilemma: when and how should specific IgE testing for food and environmental allergens shape routine eczema care? Key topics include the evolution of pathophysiology—shifting focus from allergy-driven disease to barrier dysfunction and type 2 inflammation—plus risk stratification, differential diagnosis, the role and interpretation of specific IgE tests, evidence-based guideline updates, environmental and food allergen impacts, targeted therapeutics, and practical patient counseling. Special attention is given to environmental triggers such as dust mites and pet dander and structured elimination diets. Clinicians will gain actionable insights on refining diagnostic workups, individualizing treatment plans, and supporting long-term disease control in pediatric and adult eczema populations. References and resources: https://www.thermofisher.com/phadia/us/en/resources/immunocast/eczema-essentials-atopic-dermatitis-diagnosis-management.html?cid=0ct_3pc_05032024_9SGOV4

CME credits: 1.00 Valid until: 25-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/ On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes. =

What would you do if it were your patient? Credit available for this activity expires: 12/22/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/building-case-nonsteroidal-topical-atopic-dermatitis-2025a1000zo9?ecd=bdc_podcast_libsyn_mscpedu

Unsure when to refer pediatric patients with atopic dermatitis (AD)? Learn clear criteria to streamline your decision-making. Credit available for this activity expires: 12/12/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/collaborative-care-pediatric-atopic-dermatitis-2025a1000y71?ecd=bdc_podcast_libsyn_mscpedu

Not all JAKs are the same: Learn how JAKs can help your patients. Credit available for this activity expires: 12/05/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/exploring-jak-inhibitors-atopic-dermatitis-2025a1000xqp?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

Send us a textDermatologist and clinical researcher Dr. Michael Bernhardt joins Dr. Erich Schramm to unpack the rapidly evolving science of atopic dermatitis. The two doctors discuss the symptoms, science, and treatments for atopic dermatitis, including how much clinical research has changed the landscape and improved outcomes. The two get into how the immune system drives the disease, and how new therapeutic drugs target those systems in way thats more than just skin deep.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Time is running out to access this essential CME/NCPD-approved podcast! Join renowned dermatology experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold as they dive into the latest evidence and best practices for treating atopic dermatitis in children and adolescents. With new therapies rapidly changing the treatment landscape, this podcast delivers the practical insights you need to confidently diagnose, evaluate, and manage pediatric atopic dermatitis. Don't miss your chance to: -Get up to speed on novel and emerging therapies, including nonsteroidal topicals, JAK inhibitors, and monoclonal antibodies -Learn how to recognize key clinical features that inform the differential diagnosis -Discover strategies to optimize outcomes and quality of life for your young patients This activity is expiring soon—listen now to stay current and earn credit before it's gone! Click here to claim your CME/NCPD credit: bit.ly/4nGZhBG

Episode 205: Atopic Dermatitis Kara Willbanks (medical student) explains the definition, pathophysiology, and treatment of eczema. Dr. Arreaza adds some input about bleach baths and topical steroids. Written by Kara Willbanks, MSIV, American University of the Caribbean. Comments and edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.October is the Eczema Awareness Month!What Is Atopic Dermatitis? Atopic dermatitis, a form of eczema, is a chronic, relapsing inflammatory skin disorder that often begins in childhood but can affect people of all ages. Other eczematous dermatoses include seborrheic dermatitis, contact dermatitis, juvenile plantar dermatosis, and stasis dermatitis. Atopic dermatitis is one of the most common skin conditions in the developed world, typically affecting up to 20% of children and 5-10% of adults. Patients usually present with severe pruritus (itchiness) and dry, inflamed patches of skin. Common sites include the face and extensor surfaces in infants, and flexural areas — like the elbows and knees — in older children and adults. Atopic dermatitis is often associated with other allergic conditions like asthma and allergic rhinitis — what we call the “atopic triad.” These conditions should also be considered when diagnosing someone with atopic dermatitis. PathophysiologyAtopic dermatitis is believed to occur due to a combination of genetic, immune, and environmental factors. A major component is a defective skin barrier, often linked to mutations in the filaggrin gene. This allows irritants, allergens, and microbes to penetrate the skin more easily, triggering inflammation.Differential DiagnosisAtopic dermatitis can sometimes mimic other skin conditions, so it's important to keep a differential in mind: -Contact dermatitis – triggered by allergens or irritants; often limited to the area of exposure but also tends to be very itchy. -Seborrheic dermatitis – greasy scales, typically on the scalp, eyebrows, and nasolabial folds -Psoriasis – well-demarcated plaques with silvery scales; sometimes found in similar areas of the body as eczema. -Tinea (fungal infections) – ring-shaped lesions with active, scaly borders -Important to note that treatment of tinea with topical steroids can make the rash much worse. -Scabies – intense itching, especially at night, with burrows between fingers. Ruling out these conditions helps guide the right treatment and prevent chronic mismanagement. As a recap our main differential diagnosis: contact dermatitis, seborrheic dermatitis, psoriasis, tinea, and scabies.The treatment cornerstone: Moisturizers The most important daily treatment for atopic dermatitis is regular moisturizing. Moisturizers repair the skin barrier, reduce water loss, and protect against irritants. They should be applied at least twice daily, ideally right after bathing while the skin is still damp (within 3 minutes is most ideal). Use greasy ointments or thick creams rather than lotions — think products with ceramides or glycerin (hydrates and protects skin). It is best to choose ointments or creams without additives, perfumes or fragrances. Greasier ointments are the preferred vessel; however, patient compliance may be less as they may be unpleasant to some.Bleach Baths For patients with frequent skin infections or severe eczema, dilute bleach baths can be a game-changer. How to do it? Use ¼ to ½ cup of household bleach in a full standard bathtub of water (about 40 gallons) and soak for 10 minutes, twice a week. This helps reduce bacterial colonization — particularly Staphylococcus aureus — which commonly worsens eczema. After the bath, pat the skin dry and immediately apply a moisturizer (within 3 minutes). Bleach baths are endorsed by the American Academy of Pediatrics and the American Academy of Dermatology as an adjunctive treatment for atopic dermatitis, especially in patients with moderate to severe disease and frequent bacterial infections, but the evidence for their efficacy is mixed, and further well-designed studies are needed.Medical Treatments-Topical corticosteroids: When moisturizers alone aren't enough, we move to anti-inflammatory therapy. Topical corticosteroids are the first-line treatment for flares. Some studies suggest that a short burst of a high-potency topical corticosteroid to rapidly control active disease, followed by a quick taper in potency, is most effective, whereas others use the lowest-potency agent thought to be needed and adjust upward only if this fails. Common steroids used are hydrocortisone (low potency), triamcinolone (medium potency), or betamethasone (high potency). -High-potency steroids should never be applied to sensitive skin like the face. With short-term use of lower-potency steroids, there is a low likelihood of skin atrophy but use for more than 6 months is linked with greater levels of skin thinning -Wet wrap therapy: Wet wrap therapy improves absorption of topic steroid. Apply a topical steroid, then layer a wet dressing and then a dry dressing over the top of that. This can be beneficial in providing  both relief of symptoms and prevention of itching. In pediatric patients it is called “daddy's socks therapy” because large socks may be used to cover the arms of kids.-Topical calcineurin inhibitors — like tacrolimus — are great alternatives for sensitive areas or for maintenance once inflammation is under control. They may burn upon application which can scare patients away from their use.-PO antihistamines can help with itching, especially at night, but they don't treat inflammation itself.-Systemic therapies, like dupilumab (Dupixent®), an IL-4 receptor antagonist, are reserved for moderate to severe cases unresponsive to topical therapy. This is a great time to refer to your local dermatologist for management! Many of the newer treatments are highly effective but can require more frequent monitoring.Recent Research One recent study is the 2024 Cochrane network meta-analysis comparing effectiveness of topical anti-inflammatory treatments for eczema that was recently published in the AFP Journal in July of 2025.Here are the highlights:-Over 291 RCTs with ~45,846 participants were included. -The analysis ranked potent topical corticosteroids, JAK inhibitors (for example ruxolitinib (Opzelura® 1.5 %), and tacrolimus 0.1 % among the most effective for reducing signs and symptoms of eczema. -In contrast, PDE-4 inhibitors [like crisaborole (Eucrisa®) 2 %] were among the least effective in this comparison. -Regarding side effects: tacrolimus and crisaborole were more likely to cause burning or stinging at the application site; corticosteroids were less likely in the short term to cause local irritation.-Long-term outcomes regarding effectiveness or safety of treatments for eczema were not addressed by the review because they are rarely reported.”-Another insight from this study is considering cost when initiating treatment. Most topical steroids are significantly more cost effective than JAK inhibitors or calcineurin inhibitors so it may be best to start with a cheaper solution in an uninsured patient considering their relative effectiveness. Additional Tips & Lifestyle -Keep baths and showers short and in lukewarm water.-Avoid harsh soaps and detergents — use gentle, fragrance-free cleansers.-Wear soft cotton clothing instead of wool or synthetics.-Identify and avoid triggers — common ones include stress, sweating, allergens, and certain foods (especially in kids).-Ice packs can help reduce itching and relieve any burning sensation.-Keep fingernails short, especially in children, help cause less trauma to the skin from repeated itching. Living with eczema Many celebrities like Kerry Washington, Jessica Simpson, Kelly Rowland, Brad Pitt and Kristen Bell have spoken out about their lives with eczema. They have shared personal stories about how they were diagnosed, what treatment works for them, and the general impact it has had on their lives and mental health. I feel like it can be so important for celebrities to speak out about their lives with certain conditions because it helps to normalize the condition, raise awareness of the struggles, and encourages more open dialogue.It is important to remember that for patients living with eczema, the persistent itch-scratch cycle can be very distressing, causing patients to struggle with their sleep and day-to-day activities. Anxiety and depression are common in patients with eczema so as physicians it is vital to monitor for signs of distress. Support groups can be incredibly helpful for patients [National Eczema Association]If you are interested in providing additional information to your patients or getting this for yourself, you can find more resources on altogethereczema.org or nationaleczema.org. Key Takeaways Atopic dermatitis is chronic but manageable. Moisturizers are the foundation of treatment. Topical steroids and calcineurin inhibitors control inflammation. Bleach baths help reduce bacterial load and flare severity. Always rule out other skin conditions to ensure appropriate management. Atopic dermatitis can be managed by the primary care physician but in certain cases (cases refractory to standard topical treatment, recurrent infections, etc.), a referral to dermatology can be especially helpful.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! References:Coping with eczema. Allergy & Asthma Network. (2025, May 20). https://allergyasthmanetwork.org/what-is-eczema/coping-with-eczema/.Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27. PMID: 24290431; PMCID: PMC4410183. https://pubmed.ncbi.nlm.nih.gov/24290431/.Yancey, J. R., & Green, S. (2025, July 15). Effectiveness of topical anti-inflammatory drugs for eczema. American Family Physician. https://www.aafp.org/pubs/afp/issues/2025/0700/cochrane-eczema.html.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Today we are bringing you a conversation on how topical therapies can effectively manage atopic dermatitis. Brian Keegan, MD, PhD, FAAD, a dermatologist with Princeton Dermatology, spoke with Alexa Hetzel, MS, PA-C, physician assistant with Schweiger Dermatology Group; Vikash D. Oza, MD, director of pediatric dermatology at NYU Langone; and Amy Spizuoco, DO, FAOCD, dermatologist and dermatopathologist at True Dermatology. In addition to discussing the clinical benefits and impact on patient outcomes of using topical therapies for atopic dermatitis, the panelists explored how health economics research informs treatment decisions by demonstrating the cost-effectiveness and accessibility of topical therapies. The panel also analyzed the potential health care cost savings and resource optimization achieved through strategic use of topical treatments and atopic dermatitis management.

Recap and review the top pearls from episodes #35 Atopic Dermatitis, #82 Tinea, and #95 Acne with a few members of our production team! It's Fables from the Cribside! (FFTC), our series providing a rapid review of recent Cribsiders episodes for your spaced learning.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for October 5-11, 2025: 1. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years The FDA approved roflumilast cream 0.05% for mild to moderate atopic dermatitis in children aged 2–5 years, expanding Arcutis' roflumilast portfolio. 2. Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years Nerandomilast became the first newly approved therapy for idiopathic pulmonary fibrosis in over a decade, offering a well-tolerated option that slows lung function decline. 3. LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Long-term data confirmed mirikizumab provides durable clinical, endoscopic, and quality-of-life benefits for ulcerative colitis up to four years, even in patients who failed prior advanced therapy. 4. Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension Baxdrostat met its primary endpoint in a phase 3 trial for treatment-resistant hypertension, supporting its potential role as a new option for difficult-to-control blood pressure. 5. Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis  Phase 2 data showed topical bimiralisib achieved high lesion clearance with favorable tolerability in patients with actinic keratosis.

Tom Lewis, DVM, DACVD is back on the podcast! Last year, Dr. Lewis joined the podcast last year to discuss the release of Zenrelia. One year later, he is back to discuss his experience with having this medication for a year and the relief it has provided for hundreds of his canine patients. Also, we discuss the recent change to the US boxed label warning which removed the vaccine induced disease portion of the label.Learn more on this week's episode of The Derm Vet podcast!Studies mentioned in podcast: Recent study regarding vaccine booster response in dogs receiving Zenrelia: Fent, G.M., Jacela, J., Plazola-Ortiz, R. et al. Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls. BMC Vet Res 21, 481 (2025). https://doi.org/10.1186/s12917-025-04929-zRecent study regarding safety of Zenrelia: S. Forster, C. M. Trout, S. Despa, A. Boegel, D. Berger, and S. King, “ Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial,” Veterinary Dermatology (2025): 1–13, https://doi.org/10.1111/vde.70009.Timestamps00:00 Intro02:46 Zenrelia box label warning change08:14 What does the box label warning change mean and why it's only in the US?12:10 Looking at every patient as an individual17:00 How comfortable do you feel using Zenrelia long-term?22:14 Outro

This episode is sponsored by Elanco Animal Health On this episode of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA, and Joya Griffin, DVM, DACVD, talk about how important it is for general practitioners to control pruritus quickly to retain client relationships, treatment approaches based on the severity and seasonality, and more.  You can watch the video version of this podcast on dvm360.com!

Are you talking about quality of life with your patients with atopic dermatitis (AD)? Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/atopic-dermatitis-its-more-than-skin-deep-2025a1000q26?ecd=bdc_podcast_libsyn_mscpedu

How comfortable are you with using JAK inhibitors in your practice? Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/atopic-dermatitis-balancing-act-exploring-safety-and-2025a1000q2c?ecd=bdc_podcast_libsyn_mscpedu

Simplify pediatric eczema regimens with once-daily, nonsteroidal treatments. See what's making a difference for young patients and families. Credit available for this activity expires: 9/25/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/framing-future-topical-therapies-atopic-dermatitis-2025a1000p2a?ecd=bdc_podcast_libsyn_mscpedu

Zelma Chiesa Fuxench, MD, MSCE, FAAD interviewed by Carmen Castilla, MD, FAAD

Looking to go molecule deep in atopic dermatitis? We've got just the expert. This week, we're joined by Dr. Christopher Bunick as he brings structural biology into the atopic dermatitis discourse. Listen in as he discusses cytokines, itch, and the new definition of “skin clearance.” Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Christopher Bunick, MD PhD is an Associate Professor of Dermatology at Yale School of Medicine in the Department of Dermatology. He specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at Yale School of Medicine. Chris' research has pioneered a new focus in dermatology on fundamental biochemistry and structural biology, particularly connecting the atomic resolution mechanisms of action of a therapeutic to its clinical performance and safety.   Sponsored by: LEO Pharma Visit LEO Pharma website for more information. 

Approximately 31 million people in the U.S., or 10% of the population, live with some form of eczema. But what are the different types of eczema, and why do certain types affect some people more than others? We spoke with Candrice R. Heath, MD, FAAP, FAAD, adult and pediatric dermatologist, about the eczema umbrella, treatment options, the surprising role of lifestyle factors like stress and sleep, the importance of tracking your triggers, and how to effectively partner with your doctor when it comes to managing your skin.See omnystudio.com/listener for privacy information.

In this episode Jennifer Schoch, MD, FAAD, FAAP, discusses updated guidelines for the diagnosis and treatment of atopic dermatitis or eczema. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Esli Osmanlliu, MD, and medical student Nik Jaiswal about the accuracy of large language models in pediatric and adult medicine. For resources go to aap.org/podcast.

In today's VETgirl online veterinary CE podcast, we talk to Dr. Thomas Lewis, DACVD, paid consultant for Elanco Animal Health, about managing atopic dermatitis in 2025. In veterinary medicine, we see a lot of atopic dermatitis in clinical practice. Stay up-to-date in managing atopic dermatitis, knowing when food trials are appropriate, and what new medications help make our patients comfortable! Tune in to learn how to put atopic dermatitis into remission!Sponsored By: Elanco

In today's VETgirl online veterinary CE podcast, we talk to Dr. Thomas Lewis, DACVD, paid consultant for Elanco Animal Health, about managing atopic dermatitis in 2025. In veterinary medicine, we see a lot of atopic dermatitis in clinical practice. Stay up-to-date in managing atopic dermatitis, knowing when food trials are appropriate, and what new medications help make our patients comfortable! Tune in to learn how to put atopic dermatitis into remission!Sponsored By: Elanco